L773:1876 2891
Sökning: L773:1876 2891 > Safety of Bifidobac...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04618naa a2200433 4500 | |
| 001 | oai:DiVA.org:oru-100589 | |
| 003 | SwePub | |
| 008 | 220815s2022 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-1005892 URI |
| 024 | 7 | a https://doi.org/10.3920/BM2021.01732 DOI |
| 040 | a (SwePub)oru | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Engel, S.u Chr. Hansen A/S, Human Health, Scientific Affairs, Hoersholm, Denmark4 aut |
| 245 | 1 0 | a Safety of Bifidobacterium breve, Bif195, employing a human exercise-induced intestinal permeability model :b a randomised, double-blinded, placebo-controlled, parallel group trial |
| 264 | 1 | b Wageningen Academic Publishers,c 2022 |
| 338 | a print2 rdacarrier | |
| 500 | a Funding agency:CRO Atlantia Food Clinical Trials (Cork, Ireland) | |
| 520 | a We have previously shown that the probiotic Bifidobacterium breve strain Bif195 alleviates mucosal injury including ulcer formation in the upper intestine induced by non-steroid anti-inflammatory drugs (NSAIDs). Here, we report additional safety use of Bif195 in 126 healthy humans undergoing an exercise-induced intestinal permeability challenge in a double-blinded, placebo-controlled randomised 6-week intervention trial. Intestinal permeability was assessed by urinary lactulose/rhamnose (L/R) ratio. L/R ratio, plasma intestinal fatty acid binding protein (I-FABP) and gastrointestinal symptom rating scale (GSRS) questionnaire were measured resting and after a 1 h treadmill challenge, prior to and at the end of the intervention. To be able to compare the equivalence of resting state at baseline, of this cohort of well-trained subjects, to non-trained subjects, a cohort of 63 healthy and non-trained subjects (<2 h/week of endurance sports) was included. Study subjects (well-trained) were 35.7% women with a mean age and body mass index (in kg/m2) of 35.0 years and 24.8, respectively. There were no differences between the Bif195 and placebo groups in effects on L/R ratio, I-FABP and GSRS questionnaire score. In addition, there were no differences between Bif195 and placebo in number of adverse events and change in cytokines, liver or kidney biomarkers. The exercise model successfully induced intestinal permeability by statistically significantly increasing L/R ratio by ~100% (P<0.0001) and cytokines after the exercise challenge. No significant difference was found between well-trained and non-trained subjects in baseline resting L/R ratio. In conclusion, the reported cytoprotective effects of Bif195 are unlikely to be primarily related to small bowel permeability, and the safety of Bif195 in individuals with increased permeability is supported by the present data. ClinicalTrials.gov: NCT03027583. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng |
| 653 | a Bifidobacterium breve | |
| 653 | a gastrointestinal permeability | |
| 653 | a probiotics | |
| 700 | 1 | a Mortensen, B.u Chr. Hansen A/S, Human Health, Scientific Affairs, Hoersholm, Denmark4 aut |
| 700 | 1 | a Wellejus, A.u Chr. Hansen A/S, Human Health, Scientific Affairs, Hoersholm, Denmark4 aut |
| 700 | 1 | a Vera-Jimenez, N.u Chr. Hansen A/S, Human Health, Scientific Affairs, Hoersholm, Denmark4 aut |
| 700 | 1 | a Struve, C.u Chr. Hansen A/S, Human Health, Scientific Affairs, Hoersholm, Denmark4 aut |
| 700 | 1 | a Brummer, Robert Jan,d 1957-u Örebro universitet,Institutionen för medicinska vetenskaper,Nutrition-Gut-Brain Interactions Research Centre4 aut0 (Swepub:oru)rnbr |
| 700 | 1 | a Damholt, A.u Chr. Hansen A/S, Human Health, Scientific Affairs, Hoersholm, Denmark4 aut |
| 700 | 1 | a Woods, T.u Mardyke Arena, Cork, Ireland4 aut |
| 700 | 1 | a Shanahan, F.u Department of Medicine, University College Cork, Clinical Sciences Building, Cork University Hospital, Wilton, Cork, Ireland; APC Microbiome, Biosciences Building, University College Cork, Ireland4 aut |
| 710 | 2 | a Chr. Hansen A/S, Human Health, Scientific Affairs, Hoersholm, Denmarkb Institutionen för medicinska vetenskaper4 org |
| 773 | 0 | t Beneficial Microbesd : Wageningen Academic Publishersg 13:3, s. 243-252q 13:3<243-252x 1876-2883x 1876-2891 |
| 856 | 4 | u https://doi.org/10.3920/BM2021.0173y Fulltext |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-100589 |
| 856 | 4 8 | u https://doi.org/10.3920/BM2021.0173 |
Hitta mer i SwePub
- Av författaren/redakt...
- Engel, S.
- Mortensen, B.
- Wellejus, A.
- Vera-Jimenez, N.
- Struve, C.
- Brummer, Robert ...
- visa fler...
- Damholt, A.
- Woods, T.
- Shanahan, F.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Gastroenterologi
- Artiklar i publikationen
- Beneficial Micro ...
- Av lärosätet
- Örebro universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
